Header Logo

Connection

David Lally to Retinal Vasculitis

This is a "connection" page, showing publications David Lally has written about Retinal Vasculitis.
Connection Strength

0.991
  1. Lally DR, Loewenstein A, Arnold JJ, Yang YC, Gedif K, Best C, Patel H, Tadayoni R, Heier JS. Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies. Eye (Lond). 2023 04; 37(6):1242-1248.
    View in: PubMed
    Score: 0.805
  2. Enr?quez AB, Baumal CR, Crane AM, Witkin AJ, Lally DR, Liang MC, Enr?quez JR, Eichenbaum DA. Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. 2021 Apr 01; 139(4):441-448.
    View in: PubMed
    Score: 0.186
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.